EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era
Open Access
- 11 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 49 (2), 280-286
- https://doi.org/10.1038/bmt.2013.170
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationBlood, 2012
- The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantationTransplant Immunology, 2011
- Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytesBlood, 2010
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumabBone Marrow Transplantation, 2008
- Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationBlood, 2003
- Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative diseaseBlood, 2003
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcomeBone Marrow Transplantation, 1999
- Donor T Cells to Treat EBV-Associated LymphomaNew England Journal of Medicine, 1994